Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.
about
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancySubsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma.Infectious complications of rituximab therapy in renal disease.
P2860
Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@ast
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@en
type
label
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@ast
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@en
prefLabel
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@ast
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@en
P2093
P2860
P1476
Severe and fatal adverse event ...... chemotherapy: a meta-analysis.
@en
P2093
P2860
P304
P356
10.1179/1973947815Y.0000000025
P577
2015-04-15T00:00:00Z